Colin John Meyer Reata Pharmaceuticals Inc (RETA) insider trading activity

Colin John Meyer is Chief Innovation Officer of REATA PHARMACEUTICALS INC. Currently has a direct ownership of 0 shares of RETA, which is worth approximately $0. The most recent transaction as insider was on Sep 26, 2023, when has been sold 81,633 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

100.0% 12M change

Total Value Held $0

Colin John Meyer Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 26 2023	SELL Sale (or disposition) back to the issuer	-	81,633 Reduced 100.0%	0 Class A Common Stock
Aug 16 2023	SELL Open market or private sale	$100,569 $168.74 p/Share	596 Reduced 0.72%	81,633 Class A Common Stock
Aug 15 2023	SELL Open market or private sale	$362,486 $169.07 p/Share	2,144 Reduced 2.54%	82,229 Class A Common Stock
Jul 06 2023	BUY Grant, award, or other acquisition	-	6,000 Added 6.64%	84,373 Class A Common Stock
May 16 2023	SELL Open market or private sale	$50,587 $80.94 p/Share	625 Reduced 0.79%	78,373 Class A Common Stock
May 15 2023	SELL Open market or private sale	$478,138 $85.26 p/Share	5,608 Reduced 6.63%	78,998 Class A Common Stock
Mar 07 2023	SELL Open market or private sale	$52,517 $84.57 p/Share	621 Reduced 0.73%	84,606 Class A Common Stock

Mar 03 2023	SELL Open market or private sale	$461,732 $87.35 p/Share	5,286 Reduced 5.84%	85,227 Class A Common Stock
Mar 02 2023	SELL Open market or private sale	$7,770,718 $87.67 p/Share	88,636 Reduced 49.48%	90,513 Class A Common Stock
Mar 02 2023	BUY Conversion of derivative security	-	88,636 Added 33.1%	179,149 Class A Common Stock
Feb 28 2023	BUY Grant, award, or other acquisition	-	15,000 Added 14.22%	90,513 Class A Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	23,513 Added 23.74%	75,513 Class A Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	35,000 Added 40.23%	52,000 Class A Common Stock
Jun 15 2021	SELL Open market or private sale	$5,700,800 $142.52 p/Share	40,000 Reduced 70.18%	17,000 Class A Common Stock
Jun 14 2021	SELL Open market or private sale	$2,898,000 $144.9 p/Share	20,000 Reduced 25.97%	57,000 Class A Common Stock
Jun 14 2021	BUY Conversion of derivative security	-	5,000 Added 6.1%	77,000 Class A Common Stock
Nov 17 2020	SELL Open market or private sale	$1,065,471 $166.61 p/Share	6,395 Reduced 8.16%	72,000 Class A Common Stock
Nov 17 2020	BUY Conversion of derivative security	-	6,395 Added 7.54%	78,395 Class A Common Stock
Nov 16 2020	SELL Open market or private sale	$3,219,223 $173.03 p/Share	18,605 Reduced 20.53%	72,000 Class A Common Stock
Nov 16 2020	BUY Conversion of derivative security	-	18,605 Added 17.04%	90,605 Class A Common Stock
Nov 09 2020	SELL Open market or private sale	$4,375,000 $175.0 p/Share	25,000 Reduced 25.77%	72,000 Class A Common Stock

CJM

Colin John Meyer

Chief Innovation Officer

Plano, TX

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RETA shares.

Notify only if

Value

Insider Trading

Get notified when an Reata Pharmaceuticals Inc insider buys or sells RETA shares.

Notify only if

Operation

Value

Type

News

Receive news related to REATA PHARMACEUTICALS INC

Track Activities on RETA

Account